ARO-APOC3
AROAPOC3-2002
Phase 2 small_molecule completed
Quick answer
ARO-APOC3 for Mixed Dyslipidemia is a Phase 2 program (small_molecule) at ARROWHEAD PHARMACEUTICALS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- ARROWHEAD PHARMACEUTICALS, INC.
- Indication
- Mixed Dyslipidemia
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed